← Back to Search

Non-Pharmacological Therapy

TMS for Autism

N/A

Recruiting

Led By James McPartland, PhD

Research Sponsored by Yale University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Individuals between the ages of 18 and 40 years old with typical development or with a diagnosis of autism spectrum disorder

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up measures will be recorded during the eeg/et sessions of participant visits for an expected 1-2 hours

Awards & highlights

Study Summary

This trial will study whether a brain stimulation treatment can improve social cognition in adults with ASD.

Who is the study for?

This trial is for adults aged 18-40 with autism spectrum disorder (ASD) or typical development, able to undergo EEG and eye-tracking tests. It excludes those with major psychiatric illnesses, pregnant women, individuals with an IQ below 80, history of seizures or serious medical conditions, recent drug/alcohol use, prior TMS therapy or investigational drug use within the last 12 weeks.Check my eligibility

What is being tested?

The study is testing repetitive Transcranial Magnetic Stimulation (rTMS), a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain. The goal is to see how rTMS affects social cognition in adults with ASD.See study design

What are the potential side effects?

Possible side effects of rTMS include discomfort at the stimulation site, headache, lightheadedness, tingling or spasms in facial muscles. Rarely it can cause seizures or hearing loss if ear protection isn't used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 40 years old, with or without autism.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ measures will be recorded during the eeg/et sessions of participant visits for an expected 1-2 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~measures will be recorded during the eeg/et sessions of participant visits for an expected 1-2 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and measures will be recorded during the eeg/et sessions of participant visits for an expected 1-2 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

proportion of visual attention to the eye region of the face

right hemisphere N170 latency

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Transcranial Magnetic Stimulation - realActive Control1 Intervention

Participants will receive active TMS during their study visit

Group II: Transcranial Magnetic Stimulation - shamPlacebo Group1 Intervention

Participants will receive sham stimulation during their study visit simulating TMS

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

United States Department of DefenseFED

865 Previous Clinical Trials

327,639 Total Patients Enrolled

18 Trials studying Autism Spectrum Disorder

1,680 Patients Enrolled for Autism Spectrum Disorder

Yale UniversityLead Sponsor

1,852 Previous Clinical Trials

2,738,381 Total Patients Enrolled

26 Trials studying Autism Spectrum Disorder

2,327 Patients Enrolled for Autism Spectrum Disorder

James McPartland, PhDPrincipal InvestigatorYale University

4 Previous Clinical Trials

1,241 Total Patients Enrolled

4 Trials studying Autism Spectrum Disorder

1,241 Patients Enrolled for Autism Spectrum Disorder

Media Library

Transcranial Magnetic Stimulation (TMS) (Non-Pharmacological Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04936009 — N/A

Autism Spectrum Disorder Research Study Groups: Transcranial Magnetic Stimulation - sham, Transcranial Magnetic Stimulation - real

Autism Spectrum Disorder Clinical Trial 2023: Transcranial Magnetic Stimulation (TMS) Highlights & Side Effects. Trial Name: NCT04936009 — N/A

Transcranial Magnetic Stimulation (TMS) (Non-Pharmacological Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04936009 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this clinical trial have an age restriction, and if so, what is it?

"This study is limited to individuals aged 18-40. Conversely, there are 228 trials for minors and 42 studies available to those above the age of 65."

Answered by AI

Who is able to join this research endeavor?

"This medical trial seeks to recruit 60 people between 18 and 40 years old with autism spectrum disorder or typical cognitive development. Entrants must be able to undergo an EEG and eye-tracking experiment, as these are key components of the research protocol."

Answered by AI

How many individuals have enrolled in this research endeavor?

"Affirmative. Clinicaltrials.gov reveals that this clinical trial, initially posted on March 17th 2022, is actively searching for patients to enroll in the study. 60 participants are required from 1 medical site."

Answered by AI

Does this exploration of treatments still have vacancies to join?

"Affirmative. Data on clinicaltrials.gov suggests that the trial is actively recruiting participants at this time. It was initiated on March 17th 2022 and amended most recently May 17th 2022, with a total of 60 individuals to be recruited from one location."

Answered by AI